Advertisement

Topics

Johnson & Johnson's Imbruvica Scores Expanded FDA Approval for Chronic Graft vs Host Disease

20:00 EDT 2 Aug 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Johnson & Johnson's Imbruvica Scores Expanded FDA Approval for Chronic Graft vs Host Disease

NEXT ARTICLE

More From BioPortfolio on "Johnson & Johnson's Imbruvica Scores Expanded FDA Approval for Chronic Graft vs Host Disease"

Quick Search
Advertisement